[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO3105103T3 - - Google Patents

Info

Publication number
NO3105103T3
NO3105103T3 NO15712554A NO15712554A NO3105103T3 NO 3105103 T3 NO3105103 T3 NO 3105103T3 NO 15712554 A NO15712554 A NO 15712554A NO 15712554 A NO15712554 A NO 15712554A NO 3105103 T3 NO3105103 T3 NO 3105103T3
Authority
NO
Norway
Application number
NO15712554A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3105103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3105103T3 publication Critical patent/NO3105103T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO15712554A 2013-11-05 2015-03-17 NO3105103T3 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
NO3105103T3 true NO3105103T3 (sl) 2018-05-12

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15712554A NO3105103T3 (sl) 2013-11-05 2015-03-17

Country Status (42)

Country Link
US (5) US9682939B2 (sl)
EP (1) EP3065738B1 (sl)
JP (1) JP6424231B2 (sl)
KR (1) KR102350357B1 (sl)
CN (1) CN105682656B (sl)
AP (1) AP2016009165A0 (sl)
AR (1) AR098316A1 (sl)
AU (1) AU2014346919B2 (sl)
BR (1) BR112016009630B1 (sl)
CA (1) CA2927705C (sl)
CL (1) CL2016000982A1 (sl)
CR (1) CR20160212A (sl)
CU (1) CU24375B1 (sl)
CY (1) CY1120273T1 (sl)
DK (1) DK3065738T3 (sl)
EA (1) EA030430B1 (sl)
ES (1) ES2670984T3 (sl)
GT (1) GT201600085A (sl)
HR (1) HRP20180817T1 (sl)
HU (1) HUE039155T2 (sl)
IL (1) IL245242B (sl)
JO (1) JO3454B1 (sl)
LT (1) LT3065738T (sl)
MA (1) MA39088B1 (sl)
MX (1) MX364834B (sl)
MY (1) MY175903A (sl)
NO (1) NO3105103T3 (sl)
NZ (1) NZ719078A (sl)
PE (1) PE20160682A1 (sl)
PH (1) PH12016500777B1 (sl)
PL (1) PL3065738T3 (sl)
PT (1) PT3065738T (sl)
RS (1) RS57179B1 (sl)
SG (1) SG11201603026PA (sl)
SI (1) SI3065738T1 (sl)
SV (1) SV2016005192A (sl)
TN (1) TN2016000143A1 (sl)
TR (1) TR201807321T4 (sl)
TW (1) TWI662027B (sl)
UY (1) UY35818A (sl)
WO (1) WO2015069666A1 (sl)
ZA (1) ZA201602555B (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3065738B1 (en) 2013-11-05 2018-02-28 Novartis Ag Compositions and methods for modulating farnesoid x receptors
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
EP3288948B1 (en) * 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
CN108697702A (zh) 2016-02-22 2018-10-23 诺华股份有限公司 使用fxr激动剂的方法
AR108710A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos modulares de fxr (nr1h4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
EP3512514A1 (en) * 2016-09-14 2019-07-24 Novartis AG Novel regimes of fxr agonists
CN109789119A (zh) * 2016-10-05 2019-05-21 诺华股份有限公司 用于治疗或预防纤维化、硬化疾病或障碍的含fxr激动剂的复合组合物
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
BR112019025797A2 (pt) * 2017-06-05 2020-07-07 National University Of Singapore compostos úteis na inibição do fator trefoil 3 humano
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668842A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
WO2019053582A1 (en) * 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
MX2021008518A (es) 2019-01-15 2021-08-19 Gilead Sciences Inc Compuestos que modulan fxr(nr1h4).
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
KR20220128402A (ko) 2020-01-15 2022-09-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) D형 간염 바이러스에 의한 감염을 치료하기 위한 fxr 작용제의 용도
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑
WO2024044778A2 (en) * 2022-08-26 2024-02-29 Celmatix Inc. Novel modulators of fshr and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
CN101448791B (zh) * 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
BRPI0716901B1 (pt) * 2006-09-15 2020-04-22 Thales Avionics Inc sistema para transferir conteúdo e método para entregar conteúdo entre um veículo e outra entidade
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP3065738B1 (en) 2013-11-05 2018-02-28 Novartis Ag Compositions and methods for modulating farnesoid x receptors
EP3288948B1 (en) 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors

Also Published As

Publication number Publication date
DK3065738T3 (en) 2018-06-06
IL245242A0 (en) 2016-06-30
KR102350357B1 (ko) 2022-01-14
JP2016535784A (ja) 2016-11-17
TN2016000143A1 (en) 2017-10-06
TWI662027B (zh) 2019-06-11
SI3065738T1 (sl) 2018-06-29
AR098316A1 (es) 2016-05-26
RS57179B1 (sr) 2018-07-31
JO3454B1 (ar) 2020-07-05
JP6424231B2 (ja) 2018-11-14
CN105682656A (zh) 2016-06-15
US20210253534A1 (en) 2021-08-19
LT3065738T (lt) 2018-05-10
EA201690930A1 (ru) 2016-08-31
IL245242B (en) 2019-03-31
AU2014346919A1 (en) 2016-05-12
CY1120273T1 (el) 2019-07-10
PH12016500777A1 (en) 2016-05-30
WO2015069666A1 (en) 2015-05-14
US10077240B2 (en) 2018-09-18
CU20160063A7 (es) 2016-09-30
US20170275256A1 (en) 2017-09-28
MX2016005865A (es) 2016-07-13
HRP20180817T1 (hr) 2018-06-29
US20160340317A1 (en) 2016-11-24
UY35818A (es) 2015-05-29
EP3065738B1 (en) 2018-02-28
AU2014346919B2 (en) 2017-02-02
AP2016009165A0 (en) 2016-04-30
TR201807321T4 (tr) 2018-06-21
EA030430B1 (ru) 2018-08-31
ZA201602555B (en) 2017-06-28
MX364834B (es) 2019-05-08
HUE039155T2 (hu) 2018-12-28
PE20160682A1 (es) 2016-07-23
CN105682656B (zh) 2019-11-05
KR20160079091A (ko) 2016-07-05
CL2016000982A1 (es) 2016-10-07
US20200247757A1 (en) 2020-08-06
MA39088A1 (fr) 2017-07-31
ES2670984T3 (es) 2018-06-04
NZ719078A (en) 2018-07-27
US11021446B2 (en) 2021-06-01
CU24375B1 (es) 2018-12-05
CA2927705C (en) 2021-09-21
MA39088B1 (fr) 2018-06-29
SG11201603026PA (en) 2016-05-30
PH12016500777B1 (en) 2016-05-30
TW201612163A (en) 2016-04-01
PL3065738T3 (pl) 2018-07-31
SV2016005192A (es) 2016-11-21
MY175903A (en) 2020-07-15
US10683271B2 (en) 2020-06-16
CR20160212A (es) 2016-07-22
BR112016009630A8 (pt) 2020-04-07
US20190062283A1 (en) 2019-02-28
BR112016009630B1 (pt) 2021-02-09
CA2927705A1 (en) 2015-05-14
US9682939B2 (en) 2017-06-20
EP3065738A1 (en) 2016-09-14
PT3065738T (pt) 2018-06-04
GT201600085A (es) 2019-07-19

Similar Documents

Publication Publication Date Title
NO3105103T3 (sl)
BR112015007533A2 (sl)
BR102016010778A2 (sl)
BR112014017733A2 (sl)
BR112016008313A2 (sl)
BR112014017739A2 (sl)
BR112014018502A2 (sl)
BR112014019326A2 (sl)
BR112014018516A2 (sl)
BR112014020341A2 (sl)
BR112014018480A2 (sl)
BR112014017855A2 (sl)
BR112014017765A2 (sl)
BR112014021878A2 (sl)
BR112016013531A2 (sl)
BR112016011988A2 (sl)
BR112014018468A2 (sl)
BR112014017901A2 (sl)
BR112014018207A2 (sl)
BR112014019204A2 (sl)
BR112014017722A2 (sl)
BR112015015948A2 (sl)
BR112014018578A2 (sl)
BR112014018483A2 (sl)
BR112014017794A2 (sl)